Navigation Links
Lilly Recognized as One of the World's Top Biopharmaceutical Employers
Date:10/10/2008

Science's Survey Criteria Included a Focus on Research and Respect for

People

INDIANAPOLIS, Oct. 10 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has made the list of Top 20 biopharmaceutical employers, according to the prestigious peer-reviewed journal Science. Science's 2008 survey polled nearly 4,000 employees from 500 employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. This year Lilly ranks number 10 on the list, up one position from last year's survey.

"At Lilly, our mission is to deliver innovative medicines for some of the world's most urgent unmet medical needs," said Steven Paul, M.D., executive vice president of science and technology, and president of Lilly Research Laboratories. "Core to our pipeline performance is the robust research environment here at Lilly, including excellence in both basic scientific and clinical research. Our world-renowned scientific talent has allowed Lilly to establish what we believe to be one of the best mid-stage pipelines in the industry, including 50 unique medicines - an all-time high for the company."

The web-based survey aims to determine the most reputable employers in the life science industries based on 23 characteristics, including among others, treating employees with respect, financial strength, easy adaptation to change, and a research-driven environment. The survey results appeared in today's issue of Science.

"It is an honor for Lilly to be recognized as one of the industry's top employers based on these important criteria," said John Lechleiter, Ph.D., Lilly president and chief executive officer. "Respect for people has always been a core value of Eli Lilly and Company, and this acknowledgement underscores Lilly's commitment to our employees and the patients we serve."

Approximately 25 percent of Lilly's 2007 sales came from biotech medicines; this makes the biotech portion of the company's business the equivalent of the world's fifth largest biotech company. Biotech molecules also represent approximately one-third of the company's current pipeline including potential treatments targeting Alzheimer's disease, cancer and diabetes.

About Science

Published by the American Association for the Advancement of Science (AAAS), Science ranks as the world's largest general science journal. Each week, Science provides more than 130,000 global subscribers with peer-reviewed original research, scientific research articles, science and research news and more. Science also produces a freely accessible careers website, ScienceCareers.org, offering thousands of job listings, career advice and more.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):